diabetes tagged posts

Millions of people in the U.S. are affected by diabetic retinopathy, a complication of diabetes that affects the eyes. The condition is caused by damage to the blood vessels in the retina, the light-sensitive tissue at the back of the eye. At first, diabetic retinopathy might not cause any symptoms, or the problems might be mild. However, if the underlying diabetes remains poorly managed, it can lead to blindness.

In a new study, University of Michigan researchers showed that treatment with the molecule norrin can prevent vision loss in diabetic rats. The study is published in the journal Diabetes.

Diabetic retinopathy treatment
Current therapies for diabetic retinopathy target vascular endothelial growth factor, or VEGF, a protein that causes new blood vessels to form.

VEGF a...

Most diabetes patients must carefully monitor their blood sugar levels and inject insulin multiple times per day, to help keep their blood sugar from getting too high. As a possible alternative to those injections, MIT researchers are developing an implantable device that contains insulin-producing cells. The device encapsulates the cells, protecting them from immune rejection, and it also carries an onboard oxygen generator to keep the cells healthy.

This device, the researchers hope, could offer a way to achieve long-term control of type 1 diabetes...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Orleans.

Muaaz Wajahath, from the Michigan State University College of Human Medicine in East Lansing, and colleagues evaluated the five-year risk for osteoporosis, gout, and osteomalacia in adults with both type 2 diabetes and obesity treated with GLP-1 RAs (semaglutide, liraglutide, dulaglutide, or exenatide) compared with matched controls (73,483 per group).

The researchers found that at five years, patients expo...

A pioneering study marks a major step toward eliminating the need for daily insulin injections for people with diabetes. The study was led by Assistant Professor Shady Farah of the Faculty of Chemical Engineering at the Technion—Israel Institute of Technology, in co-correspondence with MIT, and in collaboration with Harvard University, Johns Hopkins University, and the University of Massachusetts. The findings are published in the journal Science Translational Medicine.

The research introduces a living, cell-based implant that can function as an autonomous artificial pancreas, essentially a living drug that is long-term, thanks to a novel crystalline shield-protecting technology...